Access to several lines of therapy improves
outcomes in mRCC
Patients (n= 514) from UK RECCORD registry treated from March 2009 to
October 2012. Second‐line treatment was received by 15.8% of patients
Patients form IMCD receiving third‐line therapy (n= 715) or not (n = 345) from
2005 and July 2015, excluding patients who died within 3 mo of cessation
OS from time of cessation of second‐line therapy
Wagstaff J, et al. Ann Oncol 2016. Wells et al. Eur Urol 2016
